Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Editas Medicine (EDIT) over the last 11 years, with Q2 2025 value amounting to -$1.2 million.

  • Editas Medicine's Gains from Investment Securities fell 101238.1% to -$1.2 million in Q2 2025 from the same period last year, while for Sep 2025 it was -$2.3 million, marking a year-over-year decrease of 23976.43%. This contributed to the annual value of -$3.4 million for FY2024, which is 20092.95% down from last year.
  • As of Q2 2025, Editas Medicine's Gains from Investment Securities stood at -$1.2 million, which was down 101238.1% from -$1.0 million recorded in Q1 2025.
  • Editas Medicine's Gains from Investment Securities' 5-year high stood at $19.8 million during Q4 2022, with a 5-year trough of -$4.1 million in Q3 2024.
  • Its 5-year average for Gains from Investment Securities is $2.2 million, with a median of $505000.0 in 2022.
  • In the last 5 years, Editas Medicine's Gains from Investment Securities soared by 191800.61% in 2022 and then crashed by 101238.1% in 2025.
  • Over the past 5 years, Editas Medicine's Gains from Investment Securities (Quarter) stood at $983000.0 in 2021, then skyrocketed by 1918.01% to $19.8 million in 2022, then plummeted by 75.21% to $4.9 million in 2023, then tumbled by 101.22% to -$60000.0 in 2024, then tumbled by 1846.67% to -$1.2 million in 2025.
  • Its Gains from Investment Securities was -$1.2 million in Q2 2025, compared to -$1.0 million in Q1 2025 and -$60000.0 in Q4 2024.